Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

GLP-1 weight loss drugs cost CT’s Medicaid program $85 million in FY 2024, 35% of annual Medicaid pharmaceutical budget ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

A study presented at the 2025 Annual Meeting of the American Academy of Orthopaedic Surgeons examined the relationship between the patient's last dose of Ozempic, a common GLP-1, and ...

The market for GLP-1 agonist medications—used to treat diabetes and obesity—has skyrocketed in the last few years, and Lemme is “hoping to cash in on the GLP-1 agonist craze and swindle Americans into ...

MONDAY, March 10, 2025 (HealthDay News) -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic ...